ENVISION Trial Update: Integrating a New Treatment into NMIBC Standard of Care
Автор: GU Oncology Now
Загружено: 2025-09-02
Просмотров: 44
In this video series, Sandip Prasad, MD, MPhil, Atlantic Health System, provides insight into the current treatment landscape for low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and the integration of the recent FDA-approved UGN-102 treatment into clinical practice.
Here, Dr. Prasad discusses the recent ENVISION trial update and the significance of the results, which showed that among patients who achieved a complete response at 3 months after starting treatment with intravesical mitomycin, the 24-month duration of response was 72.2%. He compares UGN-102 to the previously sole treatment option for these patients and emphasizes the importance of having an additional option for clinicians to consider in collaboration with their patients.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
